In conclusion, we have shown that MDM2 inhibitor JNJ-165 induces cell death in a variety of CML cell lines with p53 mutation, including those resistant to Imatinib and harboring T315I mutation. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.